betaxolol has been researched along with carvedilol in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 6 (46.15) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Böhler, S; Figulla, HR; Saubadu, S; Scheldewaert, R | 1 |
| Abuin, L; Cotecchia, S; Lattion, A; Nenniger-Tosato, M | 1 |
| Clark, AL; Cleland, JG; Coletta, AP; Freemantle, N | 1 |
| Chochola, J; Figulla, HR; Fridl, P; Kalmbach, C; Krzeminska-Pakula, M; Wrabec, K | 1 |
| Akhmerova, RI; Gaĭfullina, RF; Ishmurzin, GP; Kim, ZF; Latfullin, IA; Podol'skaia, AA | 1 |
| Aiglova, R; Danek, J; Gloger, V; Lazarova, M; Pavlu, L; Precek, J; Schee, A; Skala, T; Taborsky, M; Vicha, M | 1 |
1 review(s) available for betaxolol and carvedilol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for betaxolol and carvedilol
| Article | Year |
|---|---|
Betaxolol versus carvedilol in chronic heart failure (BETACAR study). Rationale and design.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Betaxolol; Carbazoles; Carvedilol; Chronic Disease; Double-Blind Method; Female; Heart Failure; Humans; Male; Middle Aged; Propanolamines; Ventricular Function, Left | 1999 |
Betaxolol is equivalent to carvedilol in patients with heart failure NYHA II or III: result of a randomized multicenter trial (BETACAR Trial).
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Betaxolol; Carbazoles; Carvedilol; Double-Blind Method; Echocardiography; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Propanolamines; Retrospective Studies; Stroke Volume; Treatment Outcome | 2006 |
10 other study(ies) available for betaxolol and carvedilol
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Constitutively active mutants of the beta1-adrenergic receptor.
Topics: Adrenergic beta-1 Receptor Agonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Amino Acid Substitution; Betaxolol; Carbazoles; Carvedilol; Cell Line; Cyclic AMP; Epinephrine; Humans; Imidazoles; Isoproterenol; Labetalol; Point Mutation; Practolol; Propanolamines; Receptors, Adrenergic, beta-1; Receptors, Adrenergic, beta-2; Recombinant Proteins; Timolol | 1999 |
Clinical trials update from the European Society of Cardiology Heart Failure meeting: SHAPE, BRING-UP 2 VAS, COLA II, FOSIDIAL, BETACAR, CASINO and meta-analysis of cardiac resynchronisation therapy.
Topics: Adrenergic beta-Antagonists; Betaxolol; Carbazoles; Cardiac Pacing, Artificial; Carvedilol; Clinical Trials as Topic; Europe; Fosinopril; Heart Failure; Humans; Meta-Analysis as Topic; Propanolamines | 2004 |
[Beta-adrenoblockers for the correction of arterial hypertension in postmenopausal women].
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Betaxolol; Carbazoles; Carvedilol; Female; Humans; Hypertension; Lipids; Middle Aged; Postmenopause; Propanolamines | 2010 |
Beta-blockers utilization in heart failure patients: Sub-analysis of a nation-wide population-based study in the Czech Republic.
Topics: Adrenergic beta-Antagonists; Betaxolol; Bisoprolol; Carbazoles; Carvedilol; Czech Republic; Heart Failure; Humans; Metoprolol; Nebivolol; Propanolamines; Retrospective Studies | 2021 |